Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.

@article{Bander2005PhaseIT,
  title={Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.},
  author={Neil Harrison Bander and Matthew Ivan Milowsky and Dominika E Nanus and Lale Kostakoglu and S. Vallabhajosula and Stanley J. Goldsmith},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 21},
  pages={
          4591-601
        }
}
PURPOSE To determine the maximum tolerated dose (MTD), toxicity, human anti-J591 response, pharmacokinetics (PK), organ dosimetry, targeting, and biologic activity of (177)Lutetium-labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 ((177)Lu-J591) in patients with androgen-independent prostate cancer (PC). PATIENTS AND METHODS Thirty-five patients with progressing androgen-independent PC received (177)Lu-J591. All patients underwent (177)Lu-J591 imaging, PK, and… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 116 CITATIONS, ESTIMATED 33% COVERAGE

Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq.

  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 2017
VIEW 2 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Advances in Prostate Cancer Immunotherapies

VIEW 4 EXCERPTS
CITES RESULTS & METHODS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2005
2019

CITATION STATISTICS

  • 6 Highly Influenced Citations

  • Averaged 7 Citations per year over the last 3 years